In a groundbreaking study published in the journal Chemical Senses, scientists have unveiled critical molecular and structural alterations in taste buds that may illuminate the persistent taste loss experienced by a small subset of patients long after their COVID-19 infections have resolved. This pioneering research provides the first direct biological link between the subjective taste disturbances reported by individuals and concrete abnormalities detected within the taste receptor cells themselves.
The research was conducted by a collaborative team from the University of Colorado Anschutz and prominent Swedish universities. They conducted in-depth evaluations on 28 non-hospitalized individuals who reported ongoing taste dysfunction more than a year after contracting COVID-19. Unlike the transient taste alterations commonly seen during and shortly after the acute phase of infection, this cohort exhibited prolonged and specific deficits, with some patients demonstrating significant impairment in detecting sweet, bitter, and umami flavors, while their perception of salty and sour tastes remained largely intact.
Structurally, taste buds undergo a regular renewal cycle every two to four weeks under normal physiological conditions. However, the study’s results suggest that SARS-CoV-2 infection can cause enduring disruptions to this regenerative process in certain individuals. By performing biopsies on taste bud tissues from 20 participants, researchers identified a marked reduction in the messenger RNA (mRNA) responsible for encoding phospholipase C beta 2 (PLCβ2), a pivotal intracellular enzyme that amplifies taste signals within receptor cells attuned specifically to sweet, bitter, and umami taste qualities.
PLCβ2 plays an essential role as a molecular amplifier, boosting the initial chemical signals initiated by tastants before these signals are conveyed to the central nervous system. Corresponding author Thomas Finger, PhD, a professor of cell and developmental biology at the University of Colorado Anschutz, commented that reductions in PLCβ2 levels effectively weaken taste signaling pathways, which plausibly accounts for the diminished perception of specific tastes reported by patients. Interestingly, because salty and sour taste receptors do not rely on PLCβ2 for signal transduction, these modalities remain mostly spared, offering a biochemical explanation for the pattern of taste loss observed.
Beyond molecular disturbances, the researchers also employed microscopic examinations to uncover structural disorganization in the architecture of taste buds among several affected individuals. While some subjects preserved taste buds that appeared histologically normal, others exhibited pronounced alterations suggesting that both intrinsic molecular defects and extrinsic anatomical disruptions synergistically contribute to prolonged taste dysfunction in the aftermath of COVID-19.
The sustained nature of these tongue receptor anomalies raises compelling questions about the cellular mechanisms underlying long-term sensory deficits. The persistent downregulation of PLCβ2 mRNA and disrupted taste bud morphology contrast sharply with the expected rapid turnover of taste bud cells, implying that COVID-19 may cause a lasting impairment in cellular signaling cascades or the local microenvironment necessary for normal taste bud maintenance and regeneration.
This research holds significant implications for understanding the phenomenon often termed “long COVID,” where a constellation of symptoms—including sensory deficits such as anosmia and ageusia—persist well beyond viral clearance. These findings not only validate the subjective experiences of patients suffering from taste loss but also set the stage for developing targeted therapeutic strategies aimed at restoring normal taste function through molecular modulation or regenerative approaches.
Further studies are warranted to elucidate whether these molecular abnormalities can be reversed naturally over extended timescales or if novel pharmacological interventions might accelerate the repair and functional recovery of taste receptor cells. The integration of molecular biology, neurophysiology, and regenerative medicine could pave the way for effective treatments and enhance quality of life for those afflicted with chronic taste disorders following COVID-19.
The University of Colorado Anschutz Medical Campus, renowned for its advancements in biomedical science and patient care, facilitated this research with robust funding and interdisciplinary collaboration. This study embodies the institution’s commitment to unraveling complex biological challenges posed by emerging infectious diseases, offering hope that concrete solutions for long COVID symptoms are on the horizon.
As the investigation into post-viral sensory dysfunctions progresses, the identification of key molecular players such as PLCβ2 signifies a milestone toward a comprehensive understanding of how viruses can induce long-lasting perturbations in peripheral sensory systems. This discovery may also have broader relevance for other pathological conditions involving taste impairment.
Ultimately, these scientific advances enhance the broader field of chemosensory research and highlight the intricate relationship between infectious disease and sensory biology. They reinforce the critical need for continued inquiry into the long-term sequelae of COVID-19 to mitigate the lasting health burdens of the pandemic.
Subject of Research: People
Article Title: Taste dysfunction in long COVID
News Publication Date: 29-Jan-2026
Web References: https://academic.oup.com/chemse/advance-article/doi/10.1093/chemse/bjaf068/8444736
Keywords: COVID-19, long COVID, taste loss, taste buds, PLCβ2, molecular biology, sensory dysfunction, chemosensory system, receptor cells, virus-induced sensory impairment, post-viral sequelae, regenerative medicine
